Expanded Access Program of Neladalkib (NVL-655) for Patients With Advanced ALK+ NSCLC or Other ALK+ Solid Tumors

Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung Cancer

NCT03737994 ·Status: TERMINATED ·Phase: PHASE2

Expanded Access Program With Nivolumab Therapy for Treatment of Advanced/Metastatic SqNSCLC or Non-SqNSCLC After One Prior Systemic Regimen

NCT02475382 ·Status: NO_LONGER_AVAILABLE

Erlotinib Versus Carboplatin/Vinorelbine in Elderly Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

NCT00678964 ·Status: UNKNOWN ·Phase: PHASE2

A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid Tumors

NCT04644315 ·Status: TERMINATED ·Phase: PHASE2

Expanded Access to Rovalpituzumab Tesirine

NCT03503890 ·Status: NO_LONGER_AVAILABLE

Efficacy of Treatment Sequences in Patients With Non-small Cell Lung Cancer Receiving Lorlatinib

NCT03727477 ·Status: COMPLETED

AK112 Neoadjuvant/Adjuvant Treatment for Resectable NSCLC

NCT05247684 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

An Efficacy and Safety Study of JNJ-64041757, a Live Attenuated Listeria Monocytogenes Immunotherapy, in Combination With Nivolumab Versus Nivolumab Monotherapy in Participants With Advanced Adenocarcinoma of the Lung

NCT03371381 ·Status: TERMINATED ·Phase: PHASE1/PHASE2

Study Evaluating EKB-569 in Advanced Non-Small Cell Lung Cancer

NCT00067548 ·Status: COMPLETED ·Phase: PHASE2

A Study to Evaluate the Combination of Platinum-pemetrexed Based Chemotherapy Plus Lorlatinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) With Exclusively Extracranial Disease Progression on Lorlatinib

NCT06378892 ·Status: RECRUITING ·Phase: PHASE2

A Study of VAL401 in the Treatment of Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer

NCT02875340 ·Status: COMPLETED ·Phase: PHASE2

Study of Plasma NGS for Assessment, Characterization, Evaluation of Patients With ALK Resistance

NCT03833934 ·Status: COMPLETED

Peptide Vaccine To Prevent Acquired Resistance In Patients With Advanced ALK+ NSCLC

NCT05950139 ·Status: RECRUITING ·Phase: PHASE1/PHASE2

Study of Safety and Efficacy of Ceritinib in Combination With Nivolumab in Patients With ALK-positive Non-small Cell Lung Cancer

NCT02393625 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1

Alectinib in Neo-adjuvant Treatment of Stage III NSCLC

NCT05015010 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

A Study of XL184 (Cabozantinib) With or Without Erlotinib in Subjects With Non-Small Cell Lung Cancer (NSCLC)

NCT00596648 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

2nd Line Erlotinib Treatment With (Out) Chemotherapy of Advanced Non Small Cell Lung Cancer (NSCLC)

NCT00835471 ·Status: COMPLETED ·Phase: PHASE2

A Single-cell Approach to Identify Biomarkers of Efficacy and Toxicity for ICI in NSCLC

NCT04807114 ·Status: RECRUITING

Access Program With Denileukin Diftitox for the Treatment of Patients Currently Receiving Treatment With Commercially Available (Ontak)

NCT01432483 ·Status: NO_LONGER_AVAILABLE

NIvolumab COmbination With Standard First-line Chemotherapy and Radiotherapy in Locally Advanced Stage IIIA/B Non-Small Cell Lung Carcinoma

NCT02434081 ·Status: COMPLETED ·Phase: PHASE2

An Observational Study to Evaluate the Real-World Clinical Management and Outcomes of ALK-Positive Advanced NSCLC Participants Treated With Alectinib

NCT04764188 ·Status: ACTIVE_NOT_RECRUITING

LDK378 Versus Chemotherapy in ALK Rearranged (ALK Positive) Patients Previously Treated With Chemotherapy (Platinum Doublet) and Crizotinib

NCT01828112 ·Status: COMPLETED ·Phase: PHASE3

A Study of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer Naive to Chemotherapy

NCT02013206 ·Status: COMPLETED ·Phase: PHASE2

Neo-Adjuvant Immunotherapy With Nivolumab for Non Small Cell Lung Cancer Patients

NCT03081689 ·Status: COMPLETED ·Phase: PHASE2

Nivolumab in the Real World: Analysis of the Expanded Use in Spanish Patient

NCT03132493 ·Status: COMPLETED